Have a personal or library account? Click to login
Prospective evaluation of probabilistic dose-escalated IMRT in prostate cancer Cover

Prospective evaluation of probabilistic dose-escalated IMRT in prostate cancer

Open Access
|Dec 2020

Figures & Tables

Figure 1

Coverage probability (CovP) concept: an example case is shown to indicate CovP-internal target volume (ITV) and planning organ at risk volumes (PRVs).

Figure 2

Survival outcomes: Kaplan-Meier curves of biochemically no evidence of disease (bNED), overall survival (OS), distant metastasis-free survival (DMFS) and prostate-cancer specific survival (PCSS).

Figure 3

Late genitourinary (GU) toxicity items Radiation Therapy Oncology Group (RTOG) bladder late, common terminology criteria (CTC) urinary frequency and CTC urinary obstruction scored over the follow up (FU) period (left).Y-axis: percentage of patients reporting the toxicity item. Top X-axis: number n of patients with data available. Lower X-axis: years after radiotherapy. Right column: maximum late toxicity summed up by grade

Figure 4

Late gastrointestinal (GI) toxicity items Radiation Therapy Oncology Group (RTOG) rectum late, common terminology criteria (CTC) proctitis and CTC rectal hemorrhage scored over the follow up (FU) period (left).Y-axis: percentage of patients reporting the toxicity item. Top X-axis: Number n of patients with data available. Lower X-axis: years after radiotherapy. Right column: maximum late toxicity summed up by grade.

Patient characteristics of the study cohort

ParameterMean (min.- max.)Mediann (%)
Age at treatment (years)70 (56–83)70
Duration of radiotherapy (weeks)7.9 (7.4–8.7)7.9
Gleason-Score (n, %)
             64 (14.3 %)
             7a (3+4)15 (53.6 %)
             7b (4+3)9 (32.1 %)
cTNM (n, %)
             cT1c8 (28.6 %)
             cT2a8 (28.6 %)
             cT2b3 (10.7 %)
             cT2c9 (32.1 %)
Neoadjuvant ADT (n, %)22 (78.6 %)
             Duration of ADT (months, range)8.9 (3.0–27.0)6.0
             Initial PSA peak in ng/ml (range)9.1 (1.9–19.8)8.3
PSA-peak by subgroup
             0 < x ≤ 53 (10.7 %)
             5 < x ≤ 1015 (53.6 %)
             10 < x ≤ 158 (28.6 %)
             15 < x ≤ 202 (7.1 %)
DOI: https://doi.org/10.2478/raon-2020-0075 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 88 - 96
Submitted on: Aug 31, 2020
|
Accepted on: Nov 2, 2020
|
Published on: Dec 22, 2020
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 Daniel Wegener, Bernhard Berger, Zhoulika Outtagarts, Daniel Zips, Frank Paulsen, Martin Bleif, Daniela Thorwarth, Markus Alber, Oliver Dohm, Arndt-Christian Müller, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.